Kosari, Sam http://orcid.org/0000-0002-6737-1442
Koerner, Jane
Naunton, Mark
Peterson, Gregory M.
Haider, Ibrahim
Lancsar, Emily
Wright, David
Niyonsenga, Theo
Davey, Rachel
Funding for this research was provided by:
Capital Health Network
Article History
Received: 25 August 2020
Accepted: 21 May 2021
First Online: 11 June 2021
Declarations
:
: The trial is approved by the University of Canberra (HERC:2007), ACT Health (2019/ETH13453) and Calvary Public Hospital Bruce Human Research Ethics Committees (30-2019). The study will be conducted in compliance with NHMRC guidelines [CitationRef removed], the World Medical Declaration of Helsinki [CitationRef removed] and all amendments. The trial was registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) (ACTRN: ACTRN12620000430932) on April 1, 2020.Consent to participate will be gained at the facility level, rather than the resident level, given the impracticalities of gaining informed consent from a large population (estimated > 1500 people), many of whom are likely to have cognitive impairment; there is a low risk to participants and actions will be taken to protect of participant of privacy. Residents are able to opt out of having their data included in the study, and the process on how to do this is provided to residents and families. This consent process follows Australian NHMRC guidelines [CitationRef removed] and is consistent with comparable studies conducted in Australia [CitationRef removed, CitationRef removed].
: No individual identifiable person’s data is included in this manuscript or will be included in the future publications of the main trial results. Study findings will present aggregated resident data and will not include personal identifying details. A summary of study findings will be made available to participants.
: SK and MN are pharmacists who provide clinical consulting services to some RACFs in the ACT. Other authors have no competing interests.